drug

SEMAGLUTIDE

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about SEMAGLUTIDE: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

154Connections

0Hypotheses

1Analyses

50Outgoing

46Incoming

0Experiments

1Debates

Summary

A drug referenced in 127 knowledge graph relationships. Key connections: treats PCOS (disease); activates Ampk/Sirt1/Nf-Κb Signaling Pathway (pathway); downregulates STAR (protein).

View on Wiki →

No AI portrait yet

💊 Drug Info

Name	SEMAGLUTIDE
Key Genes/Proteins	AKT, AMPK, AMYLOID, APP
Related Diseases	ALZHEIMER'S DISEASE, APOPTOSIS, ASTROGLIOSIS, AUTOPHAGY, COGNITIVE DECLINE
Related Pathways	Ampk/Sirt1/Nf-Κb Signaling Pathway

Pathway Diagram

flowchart TD
    SEM["Semaglutide"] -->|"treats"| PCOS["PCOS"]
    SEM -->|"activates"| AMPK["AMPK/SIRT1/NF-kB pathway"]
    SEM -->|"inhibits"| GFAP["GFAP"]
    SEM -->|"prevents"| AMY["Amyloid plaque deposition"]
    SEM -->|"promotes"| COG["Cognitive capability"]
    SEM -->|"therapeutic target"| AD["Alzheimer's disease"]
    style SEM fill:#bbdefb,stroke:#0d47a1,color:#000
    style AMY fill:#ffe0b2,stroke:#e65100,color:#000
    style AD fill:#ffcdd2,stroke:#b71c1c,color:#000

Outgoing (108)

Target	Relation	Type	Str
GFAP	inhibits	protein	0.95
PCOS	treats	disease	0.95
Polycystic Ovary Syndrome	treats	disease	0.95
amyloid plaque deposition	prevents	process	0.93
AMPK/SIRT1/NF-κB Signaling Pathway	activates	pathway	0.92
cognitive capability	promotes	phenotype	0.92
Hypoxia/Reoxygenation-Induced Cardiomyocyte Injury	protects_against	disease	0.92
Alzheimer's disease	therapeutic_target	disease	0.91
blood-brain barrier	penetrates	process	0.90
OXT	activates	protein	0.90
Ampk/Sirt1/Nf-Κb Signaling Pathway	activates	pathway	0.90
Autophagy	upregulates	process	0.88
Testosterone	downregulates	compound	0.85
STAR	downregulates	protein	0.85
TLR4	inhibits	protein	0.80
cognitive function	enhances	phenotype	0.80
Insulin Resistance	treats	phenotype	0.80
OBESITY	treats	disease	0.80
AKT	activates	protein	0.80
MTOR	activates	protein	0.80
PI3K	activates	pathway	0.80
astrocytes	inhibits_overactivation	cell_type	0.80
NF-κB	inhibits	protein	0.80
microglia	inhibits_overactivation	cell_type	0.80
Alzheimer's disease	treats	disease	0.70
medullary thyroid carcinoma	associated_with	disease	0.70
glycemic control	regulates	process	0.70
neuroinflammation	inhibits	process	0.70
polycystic ovary syndrome	treats	disease	0.70
acute pancreatitis	causes	disease	0.70
Type 2 Diabetes Mellitus	treats	disease	0.70
acute kidney injury	causes	disease	0.70
TAU	treats	protein	0.70
OXIDATIVE STRESS	inhibits	phenotype	0.65
DEMENTIA	interacts_with	disease	0.65
NEURONS	protects_against	cell_type	0.65
NEURONS	activates	cell_type	0.65
NEUROINFLAMMATION	treats	phenotype	0.65
NLRP3 INFLAMMASOME	activates	pathway	0.65
AMPK	activates	gene	0.65
AMYLOID	degrades	protein	0.65
COGNITIVE DECLINE	treats	phenotype	0.65
NEUROINFLAMMATION	protects_against	phenotype	0.65
CYTOKINES	phosphorylates	phenotype	0.65
CYTOKINES	activates	phenotype	0.65
NLRP3 INFLAMMASOME	inhibits	pathway	0.65
AMYLOID	regulates	protein	0.65
ALZHEIMER'S DISEASE	protects_against	disease	0.65
APP	inhibits	gene	0.65
APP	activates	gene	0.65

Incoming (46)

Source	Relation	Type	Str
multiple endocrine neoplasia syndrome type 2	associated_with	disease	0.70
GFAP	suppressed_by	protein	0.70
medullary thyroid carcinoma	associated_with	disease	0.70
TAU	protects_against	protein	0.70
SYNAPTIC PLASTICITY	activates	phenotype	0.65
DIABETES	inhibits	disease	0.50
NEURON	inhibits	cell_type	0.50
NEUROINFLAMMATION	associated_with	phenotype	0.50
NEURODEGENERATION	associated_with	phenotype	0.50
COGNITIVE DECLINE	associated_with	phenotype	0.50
NLRP3 INFLAMMASOME	associated_with	pathway	0.45
MINOCYCLINE	associated_with	drug	0.45
INFLAMMATION	associated_with	phenotype	0.45
ALZHEIMER'S DISEASE	associated_with	disease	0.45
PI3K/AKT PATHWAY	associated_with	pathway	0.45
LIRAGLUTIDE	associated_with	drug	0.45
OXIDATIVE STRESS	associated_with	phenotype	0.45
SYNAPTIC PLASTICITY	associated_with	phenotype	0.45
DENTATE GYRUS	associated_with	brain_region	0.45
ASTROGLIOSIS	associated_with	phenotype	0.45
PARKINSON'S DISEASE	associated_with	disease	0.45
MICROGLIAL ACTIVATION	associated_with	phenotype	0.45
DAPAGLIFLOZIN	associated_with	drug	0.45
EXENATIDE	therapeutic_target	drug	0.35
RHEUMATOID ARTHRITIS	therapeutic_target	disease	0.35
RHEUMATOID ARTHRITIS	protects_against	disease	0.35
BRAINSTEM	regulates	brain_region	0.35
OBESITY	inhibits	disease	0.35
NEURODEGENERATION	regulates	process	0.35
DIABETES	regulates	disease	0.35
RAS	therapeutic_target	gene	0.35
PARKINSON'S DISEASE	therapeutic_target	disease	0.35
DOPAMINERGIC NEURONS	inhibits	cell_type	0.35
INFLAMMATION	protects_against	process	0.35
INSULIN RESISTANCE	associated_with	process	0.35
NF-KB	protects_against	gene	0.35
HEART FAILURE	regulates	disease	0.35
BRAINSTEM	inhibits	brain_region	0.35
AMPK	protects_against	gene	0.35
ALZHEIMER'S DISEASE	activates	disease	0.35
ASTROCYTES	activates	cell_type	0.35
AMYLOID	activates	protein	0.35
ALZHEIMER'S DISEASE	expressed_in	disease	0.35
FIBROBLASTS	regulates	cell_type	0.35
RAS	inhibits	gene	0.35
DEMENTIA	inhibits	disease	0.35

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
No targeting hypotheses

Mentioning Analyses (1)

Scientific analyses that reference this entity

What are the molecular mechanisms by which GLP-1RAs provide neuroprotective effe

neurodegeneration | 2026-04-14 | 0 hypotheses

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (1)

Multi-agent debates referencing this entity

The study demonstrates significant reduction in dementia risk (HR 0.63) with GLP

closed · Rounds: 4 · Score: 0.95 · 2026-04-16

Related Research

Hypotheses and analyses mentioning SEMAGLUTIDE in their description or question text

No additional research found